1178,73665,842 Selling and administration87,99184,185278,080244,109 Restructuring7,081-7,081-Total operating expenses133,203116,221393,437335,673Operating income146,070122,913408,290366,919Interest, net16,65110,91544,86231,718Other income, net(5,202)(753)(4,221)(1,945)Income from continuing operations beforeincome taxes134,621112,751367,649337,146Income tax expense18,89421,22081,72582,158Income from continuing operations115,72791,531285,924254,988Loss from discontinued operations,net of tax-(2,446)-(1,361)Net income$
115,727$
89,085$
285,924$
253,627Earnings (loss) per share (1) BasicContinuing operations$
1.24$
0.99$
3.07$
2.77Discontinued operations-(0.03)-(0.01)Basic earnings per share$
1.24$
0.96$
3.07$
2.75 DilutedContinuing operations$
1.23$
0.98$
3.04$
2.73Discontinued operations-(0.03)-(0.01)Diluted earnings per share $
1.23$
0.95$
3.04$
2.72Weighted average shares outstanding Basic93,33092,45993,15292,175 Diluted94,12493,54994,02893,371Dividends declared per share$
0.0800$
0.0700$
0.2300$
0.2025(1) The sum of individual per share amounts may not equal due to rounding.See accompanying notes to condensed consolidated financial statements.PERRIGO COMPANYCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)March 31, 2012June 25, 2011March 26, 2011AssetsCurrent assets Cash and cash equivalents$
554,280$
310,104$
223,237Accounts receivable, net560,740477,851464,190Inventories589,947505,576494,278Current deferred income taxes51,26930,47422,930Income taxes refundable7663702,103Prepaid expenses and other current assets33,88650,35050,112Current assets of discontinued operations-2,5682,797Total current assets1,790,8881,377,2931,259,647Property and equipment1,096,7491,005,798950,478 Less accumulated depreciation(532,335
'/>"/>
SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine technology :1.
Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution2.
Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel3.
Perrigo Announces FDA Final Approval for Polyethylene Glycol 33504.
Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam5.
Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 20096.
Perrigo Company Announces Dividend Increase7.
Perrigo Company Announces Quarterly Dividend8.
Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 20109.
Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference10.
Perrigo Company To Present at the Sidoti Emerging Growth Conference11.
Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix